GlassScriptPhysician profile
William David Iveson
NPI 1205232709
$2,774.57
in general payments reported to CMS, 2019-2025
23 companies · $703 in 2025
The $703 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $379 · 2022: $403 · 2023: $669 · 2024: $620 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $557.52 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $475.27 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $264.35 | 2021-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.33 | 2021-2025 | Caplyta |
| Indivior INC. | $140.54 | 2021-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $138.44 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $136.22 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Braeburn INC. | $134.14 | 2023-2025 | Brixadi |
| Novo Nordisk INC | $123.82 | 2021-2025 | Wegovy |
| Exact Sciences Corporation | $85.42 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $79.75 | 2023-2025 | |
| Abbvie INC. | $73.43 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.21 | 2022-2023 | Aralast |
| Biohaven Pharmaceutical Holding Company LTD. | $67.31 | 2022 | |
| Axsome Therapeutics, INC. | $66.85 | 2023-2024 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $60.91 | 2022-2025 | Vivitrol |
| Glaxosmithkline, LLC. | $40.64 | 2021-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $36.08 | 2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $22.42 | 2024 | Qelbree |
| Alnylam Pharmaceuticals INC. | $15.88 | 2025 | Onpattro |
| Merck Sharp & Dohme LLC | $14.85 | 2022 | |
| Dexcom, INC. | $14.42 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Iveson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.